Founded in 2020, Overland Pharmaceuticals is establishing a leading cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem.

Overland is building an initial oncology portfolio of first-in-class ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs.

Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.

Biotechnology

Health Care

Life Sciences

Therapeutics

Overland Pharmaceuticals

Ed Zhang

Wendy Yang

Sophie Chen

Eric H.

Yi-Shin Lai

Chia-Wei Chang

Weimin Li

Weijie Lan

The Leadership Team at Overland Pharmaceuticals spearheads the company's strategic direction, overseeing business development, scientific research, and operational execution. This team is responsible for forging key partnerships, guiding R&D initiatives, and ensuring the successful commercialization of innovative oncology therapies in the Greater China and Asia regions. Through their expertise, they aim to drive the company's mission of advancing promising medical technologies.

Leadership Team

Research and Development

Leadership Team

About

Team members

Other teams at Overland Pharmaceuticals

Research and Development